Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJC-1134-PC in Type 2 Diabetes Mellitus
NCT01514149Phase 2Terminated
- Sponsor
- ConjuChem
- Start
- Sep 2011
- Primary completion
- May 2012
- Modality
- Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of albenatide in type 2 diabetes mellitus (T2DM), sponsored by ConjuChem. Started Sep 2011; status: terminated.
02
Drugs
albenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01514149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01514149.